Bone metastases from differentiated thyroid carcinoma

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 37-49

  Muresan, M M ^a   Olivier, P ^a   Leclere J ^a   Sirveaux, F ^b   Brunaud, L ^a   Klein, M ^a   Zarnegar, R ^c   Weryha, G ^a  

^a CHU NANCY BRABOIS   (France)

^b Clinic for Traumatology and Orthopaedics   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CGP 69846A; CLODRONIC ACID; DENOSUMAB; DEPSIPEPTIDE; ETIDRONIC ACID RE 186; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GELDANAMYCIN; IBANDRONIC ACID; IODINE; IODINE 124; IODINE 131; LEXIDRONAM SAMARIUM SM 153; OSTEOPROTEGERIN; PAMIDRONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RADIOACTIVE IODINE; RADIOISOTOPE; ROMIDEPSIN; RS 5444; STRONTIUM 89; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CANCER GENE THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; EVOLUTION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGING; INVASIVE PROCEDURE; MICROENVIRONMENT; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PATIENT SELECTION; REVIEW; SURGICAL TECHNIQUE; SYMPTOM; THYROID CARCINOMA; TREATMENT RESPONSE; TUMOR CELL; WHOLE BODY MRI; WHOLE BODY PET;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; HUMANS; THYROID NEOPLASMS;

EID: 41349118543     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0229     Document Type: Review

References (127)

1. Aasland R, Akslen LA, Varhaug JE & Lillehaug JR 1990 Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. International Journal of Cancer 46 382-387.
2. Ahuja S & Ernst H 1987 Chemotherapy of thyroid carcinoma. Journal of Endocrinological Investigation 10 303-310.
3. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C et al. 2003 Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Research 63 2864-2871.
4. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A & Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. Journal of Clinical Oncology 22 3531-3539.
5. Alvarez L, Perez-Higueras A, Quinones D, Calvo E & Rossi RE 2003 Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life. European Spine Journal 12 356-360.
6. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE & Kubo A 1982 Survival time and 'cure' in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. Journal of Nuclear Medicine 23 561-568.
7. Bellahcene A, Albert V, Pollina L, Basolo F, Fisher LW & Castronovo V 1998 Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 8 637-641.
8. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G et al. 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 86 1568-1573.
9. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P & Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. Journal of Endocrinological Investigation 14 475-480.
10. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD et al. 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 887-892.
11. Canil CM & Tannock IF 2002 Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? Journal of National Cancer Institute 94 1422-1423.
12. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME & Busnardo B 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. Journal of Nuclear Medicine 34 1626-1631.
13. Chen KT, Lin JD, Chao TC, Hsueh C, Chang CA, Weng HF & Chan EC 2001 Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11 41-46.
14. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R & Ladenson P 2004 Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 89 91-95.
15. Chow E, Holden L, Rubenstein J, Christakis M, Sixel K, Vidmar M, Finkelstein J, Hayter C, Loblaw A, Wong R et al. 2004 Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy - a feasibility study. Radiotherapy and Oncology 70 291-294.
16. Clamp A, Danson S, Nguyen H, Cole D & Clemons M 2004 Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncology 5 607-616.
17. Clezardin P, Fournier P, Boissier S & Peyruchaud O 2003 In vitro and in vivo antitumor effects of bisphosphonates. Current Medicinal Chemistry 10 173-180.
18. Clezardin P, Ebetino FH & Fournier PG 2005 Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Research 65 4971-4974.
19. Coleman RE 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 27 165-176.
20. Coleman RE 2004 Bisphosphonates: clinical experience. Oncologist 9 (Supplement 4) 14-27.
21. Coleman RE 2006 Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research 12 6243s-6249s.
22. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J et al. 2005 Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Journal of Clinical Oncology 23 4925-4935.
23. Croucher P, Holen I & Eaton C 2005 Nonosseous effects of osteoprotegerin. Cancer Treatment Reviews 31 S14.
24. Demers LM, Costa L & Lipton A 2003 Biochemical markers and skeletal metastases. Clinical Orthopaedics and Related Research 415 (Supplement) S138-S147.
25. Dupuy DE, Monchik JM, Decrea C & Pisharodi L 2001 Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130 971-977.
26. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F et al. 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 91 2892-2899.
27. Enkaoua EA, Doursounian L, Chatellier G, Mabesoone F, Aimard T & Saillant G 1997 Vertebral metastases: a critical appreciation of the preoperative prognostic tokuhashi score in a series of 71 cases. Spine 22 2293-2298.
28. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, Pereira AM & Smit JW 2003 Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 88 3184-3189.
29. Falkmer U, Jarhult J, Wersall P & Cavallin-Stahl E 2003 A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncologica 42 620-633.
30. Fanchiang JK, Lin JD, Huang MJ & Shih HN 1998 Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years. Changgeng Yi Xue Za Zhi 21 377-382.
31. Fidler IJ 2002 Critical determinants of metastasis. Seminars in Cancer Biology 12 89-96.
32. Finlay IG, Mason MD & Shelley M 2005 Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncology 6 392-400.
33. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D, Ahrar K, Rhines LD & Gokaslan ZL 2003 Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. Journal of Neurosurgery 98 21-30.
34. Frassica DA 2003 General principles of external beam radiation therapy for skeletal metastases. Clinical Orthopaedics and Related Research 415 (Supplement) S158-S164.
35. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, Muller SP, Bockisch A, Debatin JF & Brandau W 2004 Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. European Radiology 14 2092-2098.
36. 124I. Journal of Clinical Endocrinology and Metabolism 63 918-927.
37. Gaitanis IN, Hadjipavlou AG, Katonis PG, Tzermiadianos MN, Pasku DS & Patwardhan AG 2005 Balloon kyphoplasty for the treatment of pathological vertebral compressive fractures. European Spine Journal 14 250-260.
38. Galibert P, Deramond H, Rosat P & Le Gars D 1987 Note préliminaire sur le traitement des angiomes vertébraux par vertébroplastie acrylique percutanée. Neuro-Chirurgie 33 166-168.
39. de Geus-Oei LF, Oei HY, Hennemann G & Krenning EP 2002 Sensitivity of 1231 whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 29 768-774.
40. Glinsky GV, Berezovska O & Glinskii AB 2005 Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 115 1503-1521.
41. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P & Spandidos DA 1992 Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. In Vivo 6 291-296.
42. Green JR 2003 Antitumor effects of bisphosphonates. Cancer 97 840-847.
43. Greenblatt DY & Chen H 2007 Palliation of advanced thyroid malignancies. Surgical Oncology 16 237-247.
44. Haberkorn U, Beuter P, Kubler W, Eskerski H, Eisenhut M, Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A & Altmann A 2004 Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. Journal of Nuclear Medicine 45 827-833.
45. Halpin RJ, Bendok BR & Liu JC 2004 Minimally invasive treatments for spinal metastases: vertebroplasty, kyphoplasty, and radioffequency ablation. Journal of Supportive Oncology 2 339-351.
46. Halpin RJ, Bendok BR, Sato KT, Liu JC, Patel JD & Rosen ST 2005 Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surgical Neurology 63 469-474.
47. Hindie E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, Sarfati E, Moretti JL, Bouchard P & Toubert ME 2007 Bone metastases of differentiated thyroid cancer: impact of early 1311-based detection on outcome. Endocrine-Related Cancer 14 799-807.
48. Hoie J, Stenwig AE, Kullmann G & Lindegaard M 1988 Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 61 1-6.
49. Hoskin PJ & Harmer C 1987 Chemotherapy for thyroid cancer. Radiotherapy and Oncology 10 187-194.
50. 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. Journal of Nuclear Medicine 48 889-895.
51. 131I-Na scintigraphy in the detection of metastatic thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 31 491-498.
52. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 246 466-470.
53. Keller FS, Rosch J & Bird CB 1983 Percutaneous embolization of bony pelvic neoplasms with tissue adhesive. Radiology 147 21-27.
54. Kokufu I, Kim YH, Peng YF, Fukuda K, Yamamoto M, Yano T, Yamada K & Kitano H 1998 A case of osteolytic metastases from breast cancer effectively treated with Pamidronate. Gan to Kagaku Ryoho 25 1221-1224.
55. Kokufu I, Taniguchi H, Kim YH, Fukuda K, Yamamoto M, Yano T, Yamada K & Kitano H 2000 Two bedridden patients with bone metastases from breast cancer effectively treated with Pamidronate therapy. Gan to Kagaku Ryoho 27 1751-1754.
56. Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T, Uematsu M & Kusano S 1996 Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? Journal of Nuclear Medicine 37 975-978.
57. van der Laan BF, Freeman JL & Asa SL 1995 Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5 67-73.
58. Lam MG, de Klerk JM, van Rijk PP & Zonnenberg BA 2007 Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anti-Cancer Agents in Medicinal Chemistry 7 381-397.
59. Leger AF 1995 Métastases à distance des cancers thyroïdiens différenciés. Diagnostic par l'iode 131 (I131) et traitement. Annales d'Endocrinologie 56 205-208.
60. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW, Chen JY, Li KL, Chen JF & Ho YS 1999 Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 9 1227-1235.
61. Liotta LA & Kohn EC 2001 The microenvironment of the tumour-host interface. Nature 411 375-379.
62. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordonez NG & Sherman SI 2003 Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97 1186-1194.
63. Marcocci C, Pacini F, Elisei R, Schipani E, Ceccarelli C, Miccoli P, Arganini M & Pinchera A 1989 Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 106 960-966.
64. Massin JP, Savoie JC, Gamier H, Guiraudon G, Leger FA & Bacourt F 1984 Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 53 982-992.
65. Mazzaferi E 1993 Thyroid carcinoma: papillary and follicular. In Endocrine Tumors, pp 278-333. Eds E Mazzaferi & N Saaman. Cambridge, MA: Blackwell Scientific.
66. McCormack KR 1966 Bone metastases from thyroid carcinoma. Cancer 19 181-184.
67. Mizukami Y, Michigishi T, Nonomura A, Hashimoto T, Terahata S, Noguchi M, Hisada K & Matsubara F 1990 Distant metastases in differentiated thyroid carcinomas: a clinical and pathologic study. Human Pathology 21 283-290.
68. Monchik JM, Donatini G, Iannuccilli J & Dupuy DE 2006 Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Annals of Surgery 244 296-304.
69. Monteil JP, Houlbert D, Saliba N, Despreaux G & Tran Ba Huy P 1985 Les métastases crâniennes et cervicales a caractère vasculaire des cancers thyroïdiens. A propos de 2 cas. Annales d'Oto-Laryngologie 102 53-57.
70. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC & Howell A 1988 Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 297 772-773.
71. Nagamine Y, Suzuki J, Katakura R, Yoshimoto T, Matoba N & Takaya K 1985 Skull metastasis of thyroid carcinoma. Study of 12 cases. Journal of Neurosurgery 63 526-531.
72. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M & Ramach W 1986 Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery 100 1088-1097.
73. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G & Bruland OS 2005 First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clinical Cancer Research 11 4451-4459.
74. Onimus M, Papin P & Gangloff S 1996 Results of surgical treatment of spinal thoracic and lumbar metastases. European Spine Journal 5 407-411.
75. Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ & Cance WG 1996 Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Annals of Surgical Oncology 1 100-105.
76. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, Martino E & Pinchera A 1994 Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery 18 600-604.
77. Paget S 1989 The distribution of secondary growths in cancer of the breast, 1889. Cancer Metastasis Reviews 8 98-101.
78. Pandit-Taskar N, Batraki M & Divgi CR 2004 Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. Journal of Nuclear Medicine 45 1358-1365.
79. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY & Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15 222-231.
80. Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N et al. 2002 Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB Journal 16 1266-1268.
81. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, Oetting G & Knapp WH 2001 Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. European Journal of Nuclear Medicine 28 203-208.
82. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM & Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10 261-268.
83. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE et al. 1993 Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics 25 805-813.
84. Proye CA, Dromer DH, Carnaille BM, Gontier AJ, Goropoulos A, Carpentier P, Lefebvre J, Decoulx M, Wemeau JL, Fossati P et al. 1992 Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World Journal of Surgery 16 640-645.
85. Reinbold WD, Wannenmacher M, Hodapp N & Adler CP 1989 Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. Skeletal Radiology 18 517-521.
86. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W & Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism 91 498-505.
87. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A & Giordano C 2007 BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid
88. Roodman GD 2004 Mechanisms of bone metastasis. New England Journal of Medicine 350 1655-1664.
89. Rosenthal DI 1997 Radiologic diagnosis of bone metastases. Cancer 80 1595-1607.
90. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP & Gorman CA 1988 Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. Journal of Clinical Endocrinology and Metabolism 67 501-508.
91. Ryan PJ & Fogelman I 1995 The bone scan: where are we now? Seminars in Nuclear Medicine 25 76-91.
92. Rybak LD & Rosenthal DI 2001 Radiological imaging for the diagnosis of bone metastases. Quarterly Journal of Nuclear Medicine 45 53-64.
93. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA & Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. Journal of Clinical Endocrinology and Metabolism 75 714-720.
94. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A & Pacini F 2002 Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 87 4160-4165.
95. Schirrmeister H, Buck A, Guhlmann A & Reske SN 2001 Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid 11 677-683.
96. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. New England Journal of Medicine 338 297-306.
97. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B & Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 63 960-967.
98. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M & Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. Journal of Nuclear Medicine 37 598-605.
99. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF & Baur-Melnyk A 2006 Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. European Radiology 174 939-949.
100. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E & Eilles C 2004 Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145 1031-1038.
101. Selvaggi G & Scagliotti GV 2005 Management of bone metastases in cancer: a review. Critical Reviews in Oncology/Hematology 56 365-378.
102. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine 45 1366-1372.
103. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH & DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 2155-2160.
104. Simpson WJ 1990 Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngologic Clinics of North America 23 509-521.
105. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK & Sutcliffe SB 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. International Journal of Radiation Oncology, Biology, Physics 14 1063-1075.
106. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH & Duh QY 2000 Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128 1059-1065.
107. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB & Mankoff DA 2002 Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Academic Radiology 9 913-921.
108. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L & Salvatore M 2006 Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39 35-41.
109. Tanaka M, Fushimi H, Fuji T & Ford JM 1996 Sclerosis of lytic metastatic bone lesions during treatment with Pamidronate in a patient with adenocarcinoma of unknown primary site. European Spine Journal 5 198-200.
110. Tickoo SK, Pittas AG, Adler M, Fazzari M, Larson SM, Robbins RJ & Rosai J 2000 Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Archives of Pathology & Laboratory Medicine 124 1440-1447.
111. Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H & Ohsaka S 1990 Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15 1110-1113.
112. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP & Links TP 2000 Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clinical Endocrinology 52 653-659.
113. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H & Akamaru T 2001 Surgical strategy for spinal metastases. Spine 26 298-306.
114. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J et al. 2004 AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Research 64 4931-4941.
115. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK & Sutcliffe SB 1998 The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82 375-388.
116. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J et al. 2001 Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 336-341.
117. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P & Sarrazin D 1985 External radiotherapy in thyroid cancers. Cancer 55 2062-2071.
118. Vasko VV & Saji M 2007 Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Current Opinion in Oncology 19 11-17.
119. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A & Lupoli G 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. British Journal of Cancer 84 1586-1590.
120. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J & Robbins RJ 2000 Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. Journal of Clinical Endocrinology and Metabolism 85 1107-1113.
121. Wexler JA & Sharretts J 2007 Thyroid and bone. Endocrinology and Metabolism Clinics of North America 36 673-705.
122. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D & Redini F 2004 RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta 1704 49-57.
123. Woodward JK, Coleman RE & Holen I 2005 Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 16 11-19.
124. 2+ signaling of human thyroid carcinoma cell lines. Anticancer Research 24 1617-1623.
125. Ye C, Feng C, Wang S, Liu X, Lin Y & Li M 2002 Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 143 3522-3528.
126. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY & Clark OH 2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132 984-990.
127. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R & Niederle B 2002 Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy? Clinical Endocrinology 56 377-382.